|
Groups
|
Cases
|
ANXA2
|
HE4
|
|---|
|
-
|
+
|
++
|
+++
|
Positive (%)
|
-
|
+
|
++
|
+++
|
Positive (%)
|
|---|
|
Malignant
|
84
|
4
|
25
|
27
|
28
|
95.2 %a
|
12
|
34
|
25
|
13
|
85.7 %c,d
|
|
Atypical
|
30
|
5
|
9
|
7
|
9
|
83.3 %b
|
10
|
13
|
7
|
0
|
66.7 %e
|
|
Severe
|
13
|
2
|
3
|
3
|
5
|
84.6 %
|
3
|
5
|
5
|
0
|
76.9 %
|
|
Moderate
|
9
|
1
|
3
|
3
|
2
|
88.9 %
|
2
|
5
|
2
|
0
|
77.8 %
|
|
Mild
|
8
|
2
|
3
|
1
|
2
|
75.0 %
|
5
|
3
|
0
|
0
|
37.5 %
|
|
Normal
|
18
|
8
|
2
|
1
|
7
|
55.6 %
|
15
|
3
|
0
|
0
|
16.7 %
|
|
Proliferative
|
9
|
5
|
1
|
0
|
3
|
44.4 %
|
8
|
1
|
0
|
0
|
11.1 %
|
|
Secretory
|
9
|
3
|
1
|
1
|
4
|
66.7 %
|
7
|
2
|
0
|
0
|
22.2 %
|
-
a,bpositive ANXA2 cases in malignant and atypical, respectively, compared with normal group, both p < 0.05 (p
a < 0.001, p
b = 0.049)
-
c,dpositive HE4 cases in malignant compared with atypical and normal group, respectively, both p < 0.05 (p
c = 0.023, p
d < 0.001)
-
epositive HE4 cases in atypical group campared with normal group, p < 0.05 (p
e = 0.001)
